Zenas BioPharma Prices $100M Common Stock Offering at $20.00, Concurrent with $200M Convertible Notes

summarizeSummary

Zenas BioPharma finalized its public offering of 5 million common shares at $20.00 each, raising $93.7 million net, alongside a $200 million convertible senior notes offering, to fund the commercial launch of obexelimab and pipeline development.

check_boxKey Events

• Common Stock Offering Priced

  Zenas BioPharma priced its public offering of 5,000,000 shares of common stock at $20.00 per share, a discount to the $22.16 closing price on March 26, 2026, generating approximately $93.7 million in net proceeds.

• Concurrent Convertible Notes

  The company is also conducting a concurrent public offering of $200.0 million in 2.50% Convertible Senior Notes due 2032, with an initial conversion price of $26.50 per share.

• Significant Capital Raise

  The combined offerings aim to raise approximately $300 million in gross proceeds, providing substantial capital for the planned U.S. commercial launch of obexelimab and advancement of its development pipeline.

• Dilution and Market Reaction

  This offering, along with the convertible notes, represents significant potential dilution for existing shareholders. The pricing at a discount to the prior day's close contributed to a reported 19% stock price drop following the pricing news.

auto_awesomeAnalysis

This 424B5 filing finalizes the terms and pricing of Zenas BioPharma's concurrent public offerings, which were initially announced on March 26, 2026. The company is raising a substantial amount of capital, approximately $300 million in gross proceeds, through a $100 million common stock offering priced at $20.00 per share and a $200 million convertible senior notes offering. The common stock was priced at a discount to the $22.16 closing price on March 26, 2026, which contributed to a reported 19% stock price drop following the pricing news. While this capital raise is highly dilutive for existing shareholders, it is a critical step for the company's financial stability. The funds are earmarked for the commercial launch of its lead drug candidate, obexelimab, which recently reported positive Phase 3 results, and to advance its other pipeline programs. This financing directly addresses the "going concern" warning noted in the company's recent 10-K, extending its cash runway into the third quarter of 2028. Investors should monitor the company's progress in commercializing obexelimab and advancing its pipeline, as successful execution will be crucial to offset the significant dilution.